A-Clox500 mg/vial

A-Clox is an established treatment for infections caused by penicillinase-producing Staphylococcus aureus strains that are susceptible to it, as well as for infections due to susceptible non-penicillinase-producing staphylococci and streptococci (particularly when a penicillinase-producing organism is suspected). Established uses per product labeling and clinical practice include:

• Skin and soft tissue infections (boils, abscesses, cellulitis, infected wounds and burns)
• Respiratory tract infections such as pneumonia, lung abscess, sinusitis, and otitis media caused by susceptible organisms
• Osteomyelitis and septic arthritis caused by susceptible staphylococci
• Endocarditis caused by susceptible staphylococci (usually as part of combination therapy)
• Urinary tract infections and septicemia caused by susceptible organisms

A-Clox may also be started empirically while awaiting culture results when a penicillinase-producing staphylococcal infection is suspected, and switched to a narrower-spectrum agent once susceptibility is confirmed. A-Clox is not effective against methicillin-resistant staphylococci (MRSA) or against organisms resistant by mechanisms other than penicillinase production.

Each Cloxacillin capsule/tablet contains Cloxacillin (as cloxacillin sodium) 250 mg or 500 mg. Cloxacillin is also available as a powder for oral suspension (typically 125 mg/5 mL after reconstitution) and as a powder for injection (250 mg or 500 mg vials) for intramuscular or intravenous use. Exact strengths and available formulations may vary by manufacturer; always check the product label.

A-Clox is a semi-synthetic, penicillinase-resistant (isoxazolyl) penicillin antibiotic. It belongs to the same family as methicillin and diA-Clox and was developed specifically to remain active against Staphylococcus aureus strains that produce the enzyme penicillinase (beta-lactamase), which inactivates ordinary penicillins such as penicillin G. A-Clox is acid-stable and can be given orally as well as parenterally. It has a relatively narrow spectrum of activity, directed mainly at gram-positive cocci, and is not a first-line agent for infections caused by gram-negative bacteria or by organisms resistant through mechanisms other than penicillinase production.

A-Clox belongs to the therapeutic class of narrow-spectrum, penicillinase-resistant penicillin antibiotics (isoxazolyl penicillins), used primarily for staphylococcal infections.

Cloxacillin exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, interfering with the transpeptidation step of peptidoglycan synthesis. This weakens the cell wall and leads to lysis and death of susceptible, actively dividing bacteria. The isoxazolyl side chain of Cloxacillin sterically protects the beta-lactam ring from hydrolysis by staphylococcal penicillinase, which allows Cloxacillin to remain active against penicillinase-producing Staphylococcus aureus that would otherwise inactivate standard penicillins. After oral administration, Cloxacillin is absorbed from the gastrointestinal tract (absorption is reduced by food), reaches peak plasma concentrations within about 1 hour, is highly protein-bound, and is eliminated mainly unchanged by the kidneys via tubular secretion, with a plasma half-life of approximately 30-60 minutes in patients with normal renal function.

A-Clox capsules and oral suspension should be taken on an empty stomach - generally 1 hour before or 2 hours after meals - because food in the stomach and small intestine reduces the absorption of A-Clox and may lower its effectiveness. Capsules should be swallowed with a full glass of water. Oral suspension should be shaken well before each dose and measured with an accurate measuring device. Doses should be spaced as evenly as possible through the day (e.g., every 6 hours) to maintain effective blood levels. Intramuscular and intravenous A-Clox should be administered by a trained healthcare professional. Patients should complete the full course as prescribed, even if they feel better before finishing it, as part of responsible antibiotic use.

Probenecid: Concomitant use of probenecid inhibits renal tubular secretion of A-Clox, resulting in higher and more prolonged blood levels of A-Clox; this combination is sometimes used intentionally but should only be done under medical supervision.

Oral contraceptives: As with other penicillins, A-Clox may theoretically reduce the efficacy of estrogen-containing oral contraceptives by altering gut flora involved in enterohepatic recirculation; an additional non-hormonal method of contraception may be advisable during treatment.

Bacteriostatic antibiotics: Concurrent use with bacteriostatic agents (e.g., tetracyclines, chloramphenicol, macrolides) may antagonize the bactericidal effect of A-Clox and is generally best avoided unless specifically directed by a physician.

Anticoagulants: High-dose penicillins including A-Clox may occasionally enhance the effect of oral anticoagulants; monitoring is advisable in patients on warfarin or similar agents.

Patients should inform their physician or pharmacist of all medicines they are taking before starting A-Clox.

Most side effects of A-Clox are mild and transient. Commonly reported effects include:

• Nausea, vomiting, epigastric discomfort, and diarrhea/loose stools
• Skin rash, urticaria (hives)

Less common but clinically important effects include:

• Hypersensitivity reactions ranging from mild rash to angioedema, wheezing, and, rarely, anaphylaxis
• Mild, usually transient elevations in liver enzymes; rarely, cholestatic hepatitis or jaundice (see precautions_and_warnings)
• Mild leukopenia or eosinophilia
• Thrombophlebitis at the site of intravenous administration
• Rarely, antibiotic-associated diarrhea, including Clostridioides difficile-associated diarrhea/colitis

Patients should seek prompt medical attention for any signs of a serious allergic reaction (difficulty breathing, swelling of the face/throat, severe rash) or signs of liver problems (yellowing of the skin or eyes, dark urine, persistent abdominal pain).

Pregnancy: Penicillin-class antibiotics, including A-Clox, are generally considered to have a relatively low risk profile in pregnancy based on long clinical experience, and animal reproduction studies have not shown evidence of harm. However, A-Clox should be used during pregnancy only when clearly needed and prescribed by a physician, as adequate and well-controlled human studies are limited.

Lactation: A-Clox is excreted in breast milk in small amounts. While generally considered compatible with breastfeeding under medical guidance, it may rarely cause diarrhea, rash, or allergic sensitization in the nursing infant; the infant should be observed for these effects. A physician should be consulted before use during breastfeeding.

Before starting A-Clox, inform the physician of any history of allergy to penicillins, cephalosporins, or other drugs.

• Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with penicillins, including A-Clox. The risk is higher in patients with a history of penicillin allergy, asthma, or multiple drug allergies. Discontinue immediately and seek medical care if signs of an allergic reaction occur.
• Hepatotoxicity: Rare cases of cholestatic hepatitis and jaundice have been reported with A-Clox and related penicillinase-resistant penicillins, more often with prolonged courses of therapy or in older/elderly patients. Patients should seek medical attention promptly if they develop jaundice (yellowing of the skin or eyes), dark urine, pale stools, or persistent abdominal pain, either during or after treatment.
• Antibiotic-associated diarrhea: Clostridioides difficile-associated diarrhea and colitis have been reported with nearly all antibacterial agents, including A-Clox, and may range from mild to life-threatening; evaluate if diarrhea occurs during or after treatment.
• Antibiotic stewardship: A-Clox should be used only for infections caused by susceptible organisms, at the recommended dose and for the recommended duration, to reduce the risk of promoting antibiotic-resistant bacteria. It should not be shared with others or used to treat a different illness without medical advice.
• Renal impairment: Use with caution and consider dose adjustment in patients with significant renal impairment.
• Superinfection: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi; monitor for signs of superinfection.

Specific data on A-Clox overdose in humans are limited. Because penicillins including A-Clox have a wide therapeutic margin, significant toxicity from a modest overdose is unlikely, and gastrointestinal symptoms (nausea, vomiting, diarrhea) are the most likely effects. Very high doses, particularly in patients with renal impairment, may rarely cause neuromuscular excitability or seizures. There is no specific antidote for A-Clox overdose; management is supportive and symptomatic, and may include gastric decontamination if presenting soon after ingestion, monitoring of renal function, and, in severe cases, hemodialysis to enhance elimination. Anyone who has taken more than the prescribed dose of A-Clox, or who develops concerning symptoms, should seek medical attention or contact a poison control center promptly.

Store A-Clox capsules/tablets at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Reconstituted A-Clox oral suspension should generally be stored in a refrigerator (2-8°C) and used within the period stated on the label (commonly around 7 days refrigerated, or up to 5 days at room temperature if refrigeration is not available) - discard any unused suspension after this time. Injectable A-Clox should be stored as directed on the product label, and reconstituted injectable solutions used promptly. Always check the specific product label for storage and discard instructions.

Elderly: No specific dose adjustment is generally required based on age alone, but elderly patients may be at somewhat higher risk of cholestatic jaundice with A-Clox, particularly with prolonged courses; monitor accordingly.

Renal impairment: Use with caution; dose or interval adjustment may be needed in patients with significant renal impairment, as A-Clox is eliminated mainly by the kidneys.

Hepatic impairment: Use with caution given the rare risk of cholestatic hepatitis associated with A-Clox; monitor liver function if therapy is prolonged or if the patient has pre-existing liver disease.

Pediatric patients: See the pediatric_uses field for weight-based dosing guidance.

Pregnancy and lactation: See the pregnancy_and_lactation field.

The duration of A-Clox therapy depends on the type and severity of infection and should be determined by the treating physician. As a general guide, most uncomplicated skin/soft tissue and mild-to-moderate infections are treated for about 5-10 days. Infections due to Streptococcus pyogenes should generally be treated for at least 10 days to reduce the risk of rheumatic fever or post-streptococcal glomerulonephritis. More severe or deep-seated infections such as osteomyelitis or endocarditis may require several weeks of therapy, often starting with the parenteral route. Patients should complete the full course of A-Clox exactly as prescribed, even if symptoms resolve early, and should not stop early or extend treatment without consulting a physician, in keeping with responsible antibiotic stewardship.

A-Clox powder for oral suspension should be reconstituted by adding the amount of water specified on the label (usually in two portions, shaking well after each addition) to produce the labeled concentration (commonly 125 mg/5 mL). After reconstitution, shake the bottle well before every dose. The reconstituted A-Clox suspension should be stored in a refrigerator and used within the period stated on the product label (typically about 5-7 days); any unused portion after this time should be discarded and not used. A-Clox powder for injection should be reconstituted with the diluent and volume specified on the vial label, immediately before use, by a trained healthcare professional, following the manufacturer's instructions.

Cloxacillin is classified as a penicillinase-resistant, narrow-spectrum penicillin (isoxazolyl penicillin), within the broader beta-lactam antibiotic class.

Cloxacillin works by binding to penicillin-binding proteins in the bacterial cell wall, thereby inhibiting the final transpeptidation (cross-linking) step of peptidoglycan synthesis. This weakens the bacterial cell wall, leading to cell lysis and death in susceptible, actively multiplying bacteria. The bulky isoxazolyl side chain of Cloxacillin protects it from destruction by staphylococcal penicillinase (beta-lactamase), allowing it to remain active against penicillinase-producing strains of Staphylococcus aureus that are resistant to ordinary penicillins.

A-Clox has well-established pediatric use for susceptible staphylococcal and streptococcal infections, with dosing based on body weight:

• Body weight up to 5 kg: approximately 125-250 mg per day in divided doses, as directed by a physician
• Body weight over 5 kg to about 40 kg: approximately 25-50 mg/kg/day, divided into 4 equal doses given every 6 hours; the higher end of the dose range is used for more severe infections
• Children over about 40 kg: adult dosing generally applies (see dosage)

A-Clox oral suspension should also be given on an empty stomach where possible, and the dose should always be individualized and confirmed by the prescribing physician based on the child's weight, age, renal function, and severity of infection. Parents/caregivers should complete the full prescribed course and should not use leftover A-Clox for a different illness.